losartan has been researched along with Depression in 6 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan was unable to improve hippocampal BDNF and IL-10 levels as well as the retention trial in the MWM task and depressive-like behaviors." | 5.56 | Losartan modulates brain inflammation and improves mood disorders and memory impairment induced by innate immune activation: The role of PPAR-γ activation. ( Baghcheghi, Y; Hosseini, M; Mokhtari-Zaer, A; Moradi-Marjaneh, R; Salmani, H, 2020) |
| "Losartan treatment effectively prevented increase of the hypothalamic Ang II concentration and the development of depression-like behavior, and also reduced the impairment of learning and memory in the stressed animals." | 5.56 | Tactile stimulation of adult rats modulates hormonal responses, depression-like behaviors, and memory impairment induced by chronic mild stress: Role of angiotensin II. ( Casarini, DE; Costa, R; Cunha, TS; Marcondes, FK; Moreira, RP; Nogueira, MD; Sanches, A; Tamascia, ML, 2020) |
| "Here, we show that diabetic rats exhibit depression-like behaviour, which can be therapeutically reversed by losartan." | 3.91 | Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling. ( Balogh, DB; Barczi, A; Denes, A; Farkas, T; Fekete, A; Hodrea, J; Hosszu, A; Lenart, L; Lenart, N; Szabo, AJ; Szigeti, K, 2019) |
| "Losartan was unable to improve hippocampal BDNF and IL-10 levels as well as the retention trial in the MWM task and depressive-like behaviors." | 1.56 | Losartan modulates brain inflammation and improves mood disorders and memory impairment induced by innate immune activation: The role of PPAR-γ activation. ( Baghcheghi, Y; Hosseini, M; Mokhtari-Zaer, A; Moradi-Marjaneh, R; Salmani, H, 2020) |
| "Losartan treatment effectively prevented increase of the hypothalamic Ang II concentration and the development of depression-like behavior, and also reduced the impairment of learning and memory in the stressed animals." | 1.56 | Tactile stimulation of adult rats modulates hormonal responses, depression-like behaviors, and memory impairment induced by chronic mild stress: Role of angiotensin II. ( Casarini, DE; Costa, R; Cunha, TS; Marcondes, FK; Moreira, RP; Nogueira, MD; Sanches, A; Tamascia, ML, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Salmani, H | 1 |
| Hosseini, M | 1 |
| Baghcheghi, Y | 1 |
| Moradi-Marjaneh, R | 1 |
| Mokhtari-Zaer, A | 1 |
| Costa, R | 1 |
| Tamascia, ML | 1 |
| Sanches, A | 1 |
| Moreira, RP | 1 |
| Cunha, TS | 1 |
| Nogueira, MD | 1 |
| Casarini, DE | 1 |
| Marcondes, FK | 1 |
| Lenart, L | 1 |
| Balogh, DB | 1 |
| Lenart, N | 1 |
| Barczi, A | 1 |
| Hosszu, A | 1 |
| Farkas, T | 1 |
| Hodrea, J | 1 |
| Szabo, AJ | 1 |
| Szigeti, K | 1 |
| Denes, A | 1 |
| Fekete, A | 1 |
| Christensen, KB | 1 |
| Jensen, JB | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ANGIOTENSIN AGENTS AND REDUCTION OF THE PRESCRIPTION OF ANTIDEPRESSANT DRUGS: A RETROSPECTIVE COHORT STUDY USING REAL-WORLD DATA[NCT04899206] | 120 participants (Anticipated) | Observational [Patient Registry] | 2021-04-12 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for losartan and Depression
| Article | Year |
|---|---|
Losartan modulates brain inflammation and improves mood disorders and memory impairment induced by innate immune activation: The role of PPAR-γ activation.
Topics: Amyloid beta-Peptides; Angiotensin Receptor Antagonists; Anilides; Animals; Anxiety; Behavior Rating | 2020 |
Tactile stimulation of adult rats modulates hormonal responses, depression-like behaviors, and memory impairment induced by chronic mild stress: Role of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Behavior, Animal; Cognitive Dysfun | 2020 |
Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Behavior, Animal; | 2019 |
[Cozaar (Losartan, MSD) and depression].
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Biphenyl Compounds; Depression; Depressive Disorder | 1997 |
[Losartan (Cozaar) and depression].
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Biphenyl Compounds; Depression; Depressive Disorder | 1997 |
[Drug Monitoring Board. Notice from the Adverse Effects Tribunal. Losartan (Cozaar) and depression].
Topics: Antihypertensive Agents; Depression; Female; Humans; Losartan; Male; Middle Aged | 1997 |